API Selection of Starting Materials Impact on First Cycle Approval
|
|
- Jasmin Whitehead
- 6 years ago
- Views:
Transcription
1 API Selection of Starting Materials Impact on First Cycle Approval Presented by Aloka Srinivasan, Ph.D. Vice President, Regulatory Affairs May 24, 2017
2 Trends in Selection of Regulatory Starting Materials for API Manufacturing Process Questions related to choice of Regulatory Starting Materials (RSM) for Active Pharmaceutical Ingredients (APIs) has persisted for over a decade from FDA as well as other regulatory agencies in the world FDA has been requesting the industry to define the RSM more upstream in the API manufacturing process There is a tendency in the industry to shift the RSM more and more downstream, towards the API. The inappropriate selection of RSM or lack of adequate information regarding the RSM has been and in GDUFA II, could be a major road block to first cycle approval of ANDAs
3 Some Highlights of the Regulatory Guidelines for API Starting Materials ICH Q7 defined an API starting material as follows: An API starting material is a raw material, intermediate, or an API that is used in the production of an API and that is incorporated as a significant structural fragment into the structure of the API. An API starting material can be an article of commerce, a material purchased from one or more suppliers under contract or commercial agreement, or produced in-house. API starting materials normally have defined chemical properties and structure. Drawbacks with this definition This definition of API starting material does not talk about multiple synthetically relevant steps that should separate the starting material and the final API, purging of impurities. Based on this definition of API starting material, a downstream intermediate (even the crude API), manufactured under non cgmp conditions, purchased from custom manufacturers around the world meets the ICH Q7 criteria for being a Regulatory/Key Starting Material.
4 Some Highlights of the Regulatory Guidelines for API Starting Materials ICH Q11, Development And Manufacture Of Drug Substances (Chemical Entities And Biotechnological/Biological Entities) and ICH Q11 Questions and Answers ICH Q11 provides detailed discussion on the desirable Regulatory Starting Material (RSM) Section 5.1 and 5.2 of ICH Q11 talks about the Selection of Starting Materials and Source Materials for APIs. ICH Q11 Q&A provides clarifications regarding some of the statements in ICH Q11 In spite of the clarifications in ICH Q11 Q&A guidance, the definition of what constitutes an appropriate Regulatory Starting Material in the API manufacturing process has still remained subjective. Trying to fit the science of RSM selection into regulation is like hammering a square peg in a round hole
5 Some Highlights of the Regulatory Guidelines for API Starting Materials Selected information in ICH Q11 and ICH Q11 Q&A regarding starting materials can be summarized as follows: For API manufacturing process, cgmp applies from starting material onwards, based on ICH Q7 Starting Material should be a substance of defined chemical properties and structure not a non-isolated intermediate. Starting material should contain a significant structural fragment of the API differentiates it from common agents for esterification, salt formation etc. Also, precludes defining starting materials very early in the synthetic process. For a custom synthesized starting material appropriate controls (specification, method of synthesis, impurities, reagents, catalysts) should be provided in the dossier. Also, the Pharmaceutical Quality System of the API manufacturer should address the residual risk associated with future changes in the starting material quality and process.
6 Some Highlights of the Regulatory Guidelines for API Starting Materials Selected information in ICH Q11 and ICH Q11 Q&A regarding starting materials continued: Commercially available chemicals, with pre-existing, non-pharmaceutical market need not be justified as starting material. However, if the starting material is custom made for the specific API, no matter how many sources are there, it will be considered custom synthesized and need justification. Enough of API manufacturing process must be disclosed in the dossier so that the impurity fate/purge can be understood. API manufacturing process should include a few steps upstream from those which affect the impurity profile. Manufacturing steps which impact the impurity profile of the API should be part of the process description. For a non-mutagenic impurities, if it is present in the API at a level above the ICH Q3A Identification Threshold, it is believed to have an impact on the impurity profile of the API. For a mutagenic impurity, if it is present at 30% of the ICH M7 acceptable intake in the final API, it is considered to have an impact on API quality. It needs to be established that the changes in material attributes/process conditions upstream (starting material manufacturing steps) may have lower potential to affect the API quality. If there is an impurity that persists from the starting material manufacturing process, it should be controlled adequately in the RSM and also fate/purge studies should be done to justify how it is controlled in the API.
7 An Example: Selecting the Appropriate RSM The following example is not part of any NDA/ANDA/DMF but adapted from the article in Journal of Organic Chemistry, Total Synthesis of (+)-Lysergic Acid 1 The purpose of this example of multistep synthesis is to discuss the subjective nature of the process of selection of appropriate regulatory starting materials Reference: 1. Liu Quiang et. al., J.Org.Chem, 2013, 78,
8 An Example: Selecting the Appropriate RSM (+) Lysergic Acid
9 Observations form the example Intermediate 6 has the true significant structural fragment of the fused ring system of Lysergic Acid, but is too close to the final API to be the RSM Industry may prefer to have Intermediate 6 as the RSM as the conversion of Intermediate 5 > 6 uses an expensive palladium catalyst and also has very low yield. Intermediate 5 may need significant purification. However, FDA reviewer may not be agreeable considering the fact that there are too few steps to purge the impurities from Intermediate 5 and thus conversion of 5 >6 is preferably done under very controlled conditions. Conversion of 3 > 4 will generate significant amount HCN and cyanide and thus has an impact on the impurity profile. Based on ICH Q11 Q&A, Intermediate 1, which a few steps upstream from Intermediate 3 theoretically fits the ICH Q11 definition of RSM. Intermediates 1 5, all of which have similar backbones, can be designated as a RSM based on the based on the sponsor s process controls and reviewer s prerogative
10 Challenges to Industry and FDA related to choice of RSM Challenges to industry if different sponsors are approved with different RSMs The variation in the cost of manufacturing of the API based on designated RSM may cause serious competitive disadvantage Increased load related to life cycle management, as most changes in the process downstream from RSM need to be reported to the FDA in supplements The increase in the number of cgmp steps have a potential to increase the cost of the process Challenges to FDA related to choice of RSM For the same API and a comparable process of manufacturing, different RSM for different sponsors may cause inconsistencies in the review process and time needed to approve applications Requesting that an upstream intermediate, manufactured at an outsourced facility, as an RSM makes the tracking of quality very difficult (this can lead to significant increase in cgmp related workload) Increased post approval review load as the changes downstream from RSM will need to be submitted as amendments to DMFs and supplemental applications to the ANDAs in many cases.
11 For FDA: Some points to consider related to selection of regulatory starting material: Develop a pathway for providing advice related to the proposed RSM, pre submission of the dossier (DMF or ANDA) though a formal meeting request or controlled correspondence The DMF Webpage or a relevant guidance could have the information on how a meeting request/cc can be submitted and the key information needed from the sponsor regarding the RSM selection that can help FDA make a decision Provide response to the sponsor within a given time (30 60 days) For the same process of manufacturing an API, attempt to assure consistency in the proposed RSM from sponsor to sponsor When requesting that the RSM is redefined upstream, clearly indicate the level of cgmp compliance that is being proposed: Is there going to be a FDA inspection of the manufacturer/s of the RSM? Is it adequate if the sufficient information regarding the RSM manufacturer is available to the inspector at the API manufacturing site?
12 For Industry: Some points to consider for selection of regulatory starting material: Avoid declaring a crude API, racemate of an optically active API, a salt or free base/acid of the API, an ester of a free acid or alcohol as the RSM; FDA will push back on such choices Review the vendor s manufacturing process and find out the risks associated with impurities, potentially genotoxic intermediates, reagents etc. and include controls of these in the starting material: a well controlled RSM has a greater chance of acceptance. Perform appropriate fate/purge studies to justify the starting material: this can be critical in demonstrating the low risk in your RSM selection Know the supplier of the Starting Material and evaluate if they will pass an FDA inspection, if requested by the review division.
13 Thank You We're just two lost souls Swimming in a fish bowl, Year after year, Running over the same old ground. What have we found? The same old fears. Wish you were here.
Starting Material Selection for Type II Drug Master Files
Starting Material Selection for Type II Drug Master Files Ronald S. Michalak Quality Assessment Lead (Acting), Division of Lifecycle API Office of New Drug Products, OPQ/CDER/ FDA CDER Reorganization Office
More informationRegulatory Starting Materials An FDA Perspective
Regulatory Starting Materials An FDA Perspective Kasturi Srinivasachar Branch Chief (Acting), New Drug API Division Office of New Drug Products, OPQ/CDER/ FDA 1 CDER Reorganization Office of Pharmaceutical
More informationCurrent version 13 October 2016
Implementation Working Group ICH Q11 Guideline: DEVELOPMENT AND MANUFACTURE OF DRUG SUBSTANCES (CHEMICAL ENTITIES AND BIOTECHNOLOGICAL/BIOLOGICAL ENTITIES) and Current version 13 October 2016 In order
More informationAdopted by CHMP for release for consultation 15 December Start of public consultation 15 December 2016
1 September 2017 EMA/CHMP/ICH/809509/2016 Committee for Human Medicinal Products ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological / biological
More informationICH Q11 Questions & Answers Selection & Justification of Starting Materials. Q11 Implementation Working Group 22 May 2018
IC Q11 Questions & Answers Selection & Justification of. Training Material Q11 Implementation Working Group 22 May 2018 International Council for armonisation of Technical Requirements for Pharmaceuticals
More informationICH Q11 Questions & Answers Selection & Justification of Starting Materials. Step 4 August Implementation Working Group
ICH Q11 Questions & Answers Selection & Justification of. Step 4 August 2017 Implementation Working Group International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human
More informationReflection paper on the requirements for selection and justification of starting materials for the manufacture of chemical active substances
3 July 2017 EMA/CHMP/CVMP/QWP/826771/2016 Corr. 1 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) Reflection paper on the requirements for
More informationGPhA Fall Technical Conference Nov 2-5, 2015 Bethesda, MD ICH M7 Guidance Overview and Current FDA Perspectives
GPhA Fall Technical Conference Nov 2-5, 2015 Bethesda, MD ICH M7 Guidance Overview and Current FDA Perspectives Stephen Miller, Ph.D. CMC-Lead; Office of New Drug Products Office of Pharmaceutical Quality
More informationImplementation strategy of ICH Q3D guideline
1 2 3 1 July 2016 EMA/404489/2016 Committee for Medicinal Products for Human use (CHMP) 4 5 Draft Draft agreed by QWP and BWP June 2016 Adopted by CHMP for release for consultation June 2016 Start of public
More informationImplementation strategy of ICH Q3D guideline
08 March 2017 EMA/CHMP/QWP/115498/2017 Committee for Medicinal Products for Human use (CHMP) Draft agreed by QWP and BWP June 2016 Adopted by CHMP for release for consultation June 2016 Start of public
More informationANDAs: Stability Testing of Drug Substances and Products- Industry Perspective
GPhA/FDA FALL TECHNICAL CONFERENCE ANDAs: Stability Testing of Drug Substances and Products- Industry Perspective Nick Cappuccino, Jr., Ph.D., Vice President Scientific Affairs, Dr. Reddy s Laboratories,
More informationDrug Substance Review in the Office of Pharmaceutical Quality
Drug Substance Review in the Office of Pharmaceutical Quality GPhA 2015 CMC Workshop Bethesda, MD June 9, 2015 M. Scott Furness, Ph.D. Deputy Director, Office of New Drug Products Office of Pharmaceutical
More informationThe place of the Certification Procedure in the global regulatory environment
The place of the Certification Procedure in the global regulatory environment 19-20/09/2017 - Prague Workshop 1: how to build up a good CEP application Top ten deficiencies Cristian SAMPAOLESI Reference
More informationRegulatory expectations on impurities in drug substances - Pavia, October 2, Luisa Torchio Euticals SpA
Regulatory expectations on impurities in drug substances - Pavia, October 2, 2015 Luisa Torchio Euticals SpA An Impurity is defined as any substance or element present in a drug substance (DS) that is
More informationICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities)
May 2011 EMA/CHMP/ICH/425213/2011 ICH/ Committee for medicinal products for human use (CHMP) ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological
More informationGuidance for Industry
Draft-t for Implementation Guidance for Industry ANDAs: Impurities in Drug Substances DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
More informationIMPURITIES IN NEW DRUG PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Recommended for
More information2017 AAM CMC Workshop
2017 AAM CMC Workshop SETTING PROPER IMPURITIES LIMITS - INCLUDING GENOTOXIC IMPURITIES INDUSTRY PERSPECTIVE Janet Vaughn, Sr. Director Regulatory Affairs Teva Pharmaceuticals USA 23 May, 2017 Disclaimer
More informationEU Regulatory Perspective and Expectations. Sven-Erik Hillver Senior expert, QWP delegate Medical Products Agency, Sweden
EU Regulatory Perspective and Expectations Sven-Erik Hillver Senior expert, QWP delegate Medical Products Agency, Sweden Disclaimer EU regulators still have to build up an experience of applications based
More informationM7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk
M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk This draft guidance, when finalized, will represent the Food and Drug Administration's
More informationGuidance for Industry Q3B(R2) Impurities in New Drug Products
Guidance for Industry Q3B(R2) Impurities in New Drug Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics
More informationICH Topic Q 3 A Impurities Testing Guideline: Impurities in New Drug Substances
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit CPMP/ICH/142/95 ICH Topic Q 3 A Impurities Testing Guideline: Impurities in New Drug Substances Step 5 NOTE
More informationImpurities from degradation of Drug Substances
Impurities from degradation of Drug Substances REFERENCE 1. ICH - IMPURITIES IN NEW DRUG SUBSTANCES - Q3A(R2) 2. ICH - IMPURITIES IN NEW DRUG PRODUCTS - Q3B(R2) 3. ICH - VALIDATION OF ANALYTICAL PROCEDURES:
More informationICH Q11 Development & manufacture of drug substances
ICH Q11 Development & manufacture of drug substances Keith McDonald Group Manager Medicines & Healthcare products Regulatory Agency (UK) 2011 ICH International Conference on Harmonisation of Technical
More informationICH Q3D. Questions & Answers Q1: Q2: U n d e r s ta n d i n g the Risk Assessment Requirements. Knowing the Options
ICH Q3D Questions & Answers Understanding the Risk Assessment Requirements Knowing the Options Controlling for Elemental Impurities Responsibilities U n d e r s ta n d i n g the Risk Assessment Requirements
More informationICH guideline M7 on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk
February 2013 EMA/CHMP/ICH/83812/2013 ICH guideline M7 on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk Step 3 Transmission to CHMP
More informationVICH Topic GL10. Step 7 (after revision at step 9) GUIDELINE ON IMPURITIES IN NEW VETERINARY DRUG SUBSTANCES
European Medicines Agency Veterinary Medicines and Inspections London, 19 February 2007 Doc. Ref.EMEA/CVMP/VICH/837/99-Rev.1 VICH Topic GL10 Step 7 (after revision at step 9) GUIDELINE ON IMPURITIES IN
More informationCMC Considerations for 505(b)(2) Applications. Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C.
CMC Considerations for 505(b)(2) Applications Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C. October 2011 1 Introduction Outline Brief overview of FDA drug approval pathways
More informationHow we set specifications for impurities (including Genotoxic impurities) 24 May 2017 Elisabeth Kovacs, Apotex CSO Chemistry and Analytical Sci.
2017 AAM CMC Workshop How we set specifications for impurities (including Genotoxic impurities) 24 May 2017 Elisabeth Kovacs, Apotex CSO Chemistry and Analytical Sci. The information within this presentation
More informationInternational Pharmaceutical Excipients Council Of The Americas
October 6, 2008 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Subject: FDA Draft Guidance for Industry, Residual Solvents in Drug
More informationRegulation of Active Pharmaceutical Ingredients (API)
Regulation of Active Pharmaceutical Ingredients (API) Stephan Rönninger Head External Affairs Europe, International Quality June 21, 2013 SINDUSFARMA / ANVISA / FIP-IPS Conference, Brasilia Agenda Regulations
More informationQuality by Design: An Attempt to Jumpstart. Peter Calcott, Ph.D. President, Calcott Consulting
Quality by Design: An Attempt to Jumpstart Innovation Into the Manufacturing Process Peter Calcott, Ph.D. President, Calcott Consulting GMP in the 21 st Century Quality by Design (QbD) is part of Critical
More informationHetero Drugs Limited
Global Challenges in Quality Assurance of APIs The Perspective of Indian Manufacturers Slide 1 of 30 1 Slide 2 of 30 2 Laws Governing GMPs/Quality United States Food, Drugs and Cosmetics Act Europe European
More informationNew Drug Product Impurities
Title Page Image - with courtesy of the FDA CDER original web site at www. cder.fda.gov/ New Drug Product Impurities IAGIM Scientific Committee Block JD; Holmann E ; West P NEW DRAFT GUIDANCE FDA Viewpoint
More informationRisk Management: FDA and Industry Experience. Dan Snider, Ph.D Vice President Morgantown RD Mylan Pharmaceuticals Inc.
Risk Management: FDA and Industry Experience Dan Snider, Ph.D Vice President Morgantown RD Mylan Pharmaceuticals Inc. Disclaimer This presentation contains a summary of the opinion and perspective from
More informationTHE NEW QUALITY PARADIGM OPPORTUNITIES AND EXPECTATIONS IN ICH Q8 Q9 Q10 Q11 DR. FRITZ ERNI
THE NEW QUALITY PARADIGM IN ICH Q8 Q9 Q10 Q11 OPPORTUNITIES AND EXPECTATIONS DR. FRITZ ERNI FRITZ@ERNI.NET THE NEW PARADIGM OR QUALITY BY DESIGN Why do we need it! Some background Information The impact
More informationA Generic Industry Perspective on Establishing Impurity Limits And a Corresponding Control Strategy
A Generic Industry Perspective on Establishing Impurity Limits And a Corresponding Control Strategy Nicholas Cappuccino, PhD Vice-President, Head of Quality and Scientific Affairs Dr. Reddy s Laboratories,
More informationGuideline on assessment and control of DNA reactive (mutagenic) impurities in veterinary medicinal products
1 2 3 24 February 2017 EMA/CVMP/SWP/377245/2016 Committee for Medicinal Products for Veterinary Use (CVMP) 4 5 6 Guideline on assessment and control of DNA reactive (mutagenic) impurities in veterinary
More informationAPI Testing Requirements to Support the EI Risk Assessment. Elisabeth Corbett Associate Director, GRS-CMC, Bristol-Myers Squibb November 9, 2016
API Testing Requirements to Support the EI Risk Assessment Elisabeth Corbett Associate Director, GRS-CMC, Bristol-Myers Squibb November 9, 2016 Agenda Background Review of ICH Q3D Risk Assessment Principles
More informationCANADA (HEALTH CANADA)
1 GMP GAZETTE TM May 2016 HPFBI CANADA (HEALTH CANADA) No updates NNHPD NHPs Final Monograph for Antiseptic Skin Cleanser Who`s Affected? Companies seeking NPN or DIN for topical antiseptic hand cleansers
More informationBRIEFING. . Over time, 466 may be used less frequently and may be withdrawn.
Page 1 of 13 BRIEFING 1086 USP 37 page 828. As part of an ongoing monograph modernization initiative, the United States Pharmacopeial Convention (USP) is updating this general chapter, 1086 Impurities
More informationICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon
ICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon 9 November 2016 Disclaimer The views and opinions expressed in this presentation are those of the author
More informationQuestions and answers on the 'Guideline on the limits of genotoxic impurities'
23 September 2010 EMA/CHMP/SWP/431994/2007 Rev. 3 Committee for Medicinal Products for Human Use (CHMP) Safety Working Party (SWP) Questions and answers on the 'Guideline on the limits of genotoxic impurities'
More informationFAQ: Active Pharmaceutical Ingredient Master Files (APIMFs)
(APIMFs) Electronic Formatting Will electronic signatures be accepted? Electronic signatures will be accepted on the basis that they form part of the submission and are therefore covered by declarations
More informationHow to Avoid Common Deficiencies in INDs and NDAs. Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER
How to Avoid Common Deficiencies in INDs and NDAs Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER 1 Structure of FDA Office of Commissioner Chief Scientist FOODS Medical Products & Tobacco
More informationCGMP Requirements for Investigational Products
PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health
More informationEuropean reflections on reviewing NDAs and ANDAs for ICH Q3D elemental impurity compliance
European reflections on reviewing NDAs and ANDAs for ICH Q3D elemental impurity compliance Diana van Riet-Nales, Medicines Evaluation Board/NL NL CHMP/CVMP Quality Working Party delegate (humans) Former
More informationRegulatory Review Considerations of Drug-Linker Quality in ADCs
Regulatory Review Considerations of Drug-Linker Quality in ADCs Xiao Hong Chen, Ph.D. Acting Quality Assessment Lead Division of New Drug Products I, Branch II ONDP/OPQ/CDER/FDA Outlines ADC IND submissions
More informationGuidance for Industry
Guidance for Industry ANDAs: Blend Uniformity Analysis DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should
More informationPhRMA Perspectives on Drug Substance Regulatory Filing Issues
PhRMA Perspectives on Drug Substance Regulatory Filing Issues Starting Material, Reprocessing, Retesting, and Critical Controls Tom Cupps, Betsy Fritschel, Wendy Mavroudakis, Michael Mitchell,* Dave Ridge,
More informationOverview of comments received on 'Draft Guideline on the chemistry of active substances (veterinary) (EMA/CVMP/QWP/49477/2017)
23 October 2017 EMA/CVMP/QWP/502315/2017 Committee for Medicinal Products for Veterinary Use (CVMP) Overview of comments received on 'Draft Guideline on the chemistry of active substances (veterinary)
More informationIntroduction to CMC Regulatory Affairs
Introduction to CMC Regulatory Affairs Bharathi Mamidipudi Regulatory Affairs Consultant II Syner-G Pharma Consulting, LLC Northeastern University, Boston November 10, 2016 My Background Experience ~4
More informationGuideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission
1 2 3 25 April 2014 EMA/CHMP/BWP/187338/2014 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on process validation for the manufacture of biotechnology-derived active substances
More informationScientific Considerations for Continuous API Manufacturing
Scientific Considerations for Continuous API Manufacturing Thomas O Connor, Ph.D. Office of Pharmaceutical Quality/Office of Testing and Research US FDA Center for Drug Evaluation and Research FDA PQRI
More informationControl strategy and validation. Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA
Control strategy and validation Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA 1 Disclaimer The views and opinions expressed in this presentation are those of the speaker and should not
More informationImpact factor: 3.958/ICV: 4.10 ISSN:
Impact factor: 3.958/ICV: 4.10 ISSN: 0976-7908 24 Pharma Science Monitor 8(2), Apr-Jun 2017 PHARMA SCIENCE MONITOR AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES Journal home page: http://www.pharmasm.com
More informationFDA Guidance and Current Experience with New Drug Submissions
FDA Guidance and Current Experience with New Drug Submissions Danae Christodoulou, Ph.D. CDER/OPQ Office of New Drug Products This presentation reflects the views of the author and should not be construed
More informationWHO guidelines on variations to a prequalified product
Annex 3 WHO guidelines on variations to a prequalified product Introduction 96 1. Background 97 1.1 Objectives 97 1.2 Scope and application 98 2. Guidance for implementation 99 2.1 s 99 2.1.1 Notifications
More informationStatement of David G. Strunce President and Chief Executive Officer Scientific Protein Laboratories LLC
Photos from SPL Statement of David G. Strunce President and Chief Executive Officer Scientific Protein Laboratories LLC Subcommittee on Oversight and Investigations Committee on Energy and Commerce United
More informationWhile the recognition
Designing the Perfect Change Control System Change control systems today are expected to be designed in a way that provides a system to not only document and approve changes, but also to anticipate change
More informationElemental impurities impact on APIs
Regulatory Expectations on impurities in Drug Substances: Authority and Industry perspective Pavia, 2nd October 2015 Elemental impurities impact on APIs October 2 nd 2015 Annalisa Scali RegulatoryAffairsManager
More informationFlexible and Pending Monographs
Flexible and Pending Monographs USP Approaches to Accommodate Multiple Approved Products Doreen McDonald Senior National Account Manager U.S. Pharmacopeial Convention Flexible Monographs: Background From
More informationGuidance for Industry
Guidance for Industry ANDAs: Impurities in Drug Products DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should
More informationOn the Q&A to the Guideline for Common Technical Documents
To: Public Health Bureau Prefectural Government Letter from PFSB/ELD 22 nd October 2001 From: Evaluation & Licensing Division, Pharmaceutical & Food Safety Bureau, The Ministry of Health, Labour and Welfare
More informationSubpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.
FDA inspections continue to focus on CGMP violations related to basic GMP controls. A survey of Warning Letters issued in 2013 on CMC (Chemistry / Manufacturing / Controls) violations reveals an emphasis
More informationCleaning and Cleaning Validation of API Plant and Equipment
Regulatory Basis: FDA Quality Systems Regulations Reference: FDA CFR - Code of Federal Regulations Title 21 1 Purpose The purpose of this guideline is: To define the requirements for cleaning plant and
More informationInnovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing
Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from
More informationStrategies for IND Filing Success: Chemistry, Manufacturing and Controls
Strategies for IND Filing Success: Chemistry, Manufacturing and Controls October 21, 2016 Presented by: Sharon Ayd, Ph.D., MBA Chief Scientific Officer and SVP, Pharmaceuticals document contains proprietary
More informationGMP The Other Side of Chemistry, Manufacturing & Controls (CMC)
Overview of USFDA Drug Regulatory Requirements Pharmaceutical Quality and Facility Inspections (GMP) Session II 19 February 2014 Casablanca, Morocco GMP The Other Side of Chemistry, Manufacturing & Controls
More informationStatus of the ICH Q11 Guideline on Development and Manufacture of the Active Substance. Riccardo Luigetti Prague, 9 December 2009
European Medicines Agency Status of the ICH Q11 Guideline on Development and Manufacture of the Active Substance Riccardo Luigetti Prague, 9 December 2009 The views presented in these slides are those
More informationCertification of suitability to the Monographs of the European Pharmacopoeia
AMM/CB PUBLIC DOCUMENT (LEVEL 1) English only/anglais seulement Strasbourg, September 2018 Certification of suitability to the Monographs of the European Pharmacopoeia GUIDELINE ON REQUIREMENTS FOR REVISION/RENEWAL
More informationGuidance Document 01 January 2016 CONTENTS. 1. Introduction Background 1.2. Objectives 1.3. Scope and application 1.4 APIMF holder obligations
GUIDANCE ON AMENDMENTS TO AN ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) SUBMITTED IN SUPPORT OF A PREQUALIFIED PHARMACEUTICAL PRODUCT (FPP) OR PREQUALIFIED ACTIVE PHARMACEUTICAL INGREDIENT (API)
More informationGuidance for Industry ANDAs: Stability Testing of Drug Substances and Products
Guidance for Industry ANDAs: Stability Testing of Drug Substances and Products DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this
More information5. Changes to a CEP or to a confirmation of API-prequalification document 106
Annex 3 WHO guidelines on variations to a prequalified product Introduction 96 1. Background 97 1.1 Objectives 97 1.2 Scope and application 98 2. Guidance for implementation 99 2.1 s 99 2.1.1 Notifications
More informationPost approval change of Japanese registration dossiers and impact on market supply
Post approval change of Japanese registration dossiers and impact on market supply Table of content Table of content Business model evolution of API sales Challenge on Regulatory compliance Risks of Regulatory
More informationICH Q12 Perspectives: The Robust PQS
ICH Q12 Perspectives: The Robust PQS PQRI October 5 th, 2015 Mahesh Ramanadham, Pharm.D./MBA Branch Chief, Inspection Assessment Branch 2 Division of Inspection Assessment Office of Process and Facilities
More informationICH Topic Q 3 B Impurities in New Medicinal Products
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit ICH Topic Q 3 B Impurities in New Medicinal Products Step 4, Consensus Guideline, 6 November 1996 TE FOR GUIDANCE
More informationQuality Agreement. by and between. Supplier Name. Address: and. Client Name: Address:
NOTE TO USERS This Quality Agreement template was developed by the Bulk Pharmaceutical Task Force (BPTF), an affiliate organization of the Society of Chemical Manufacturers and Affiliates (SOCMA), as a
More informationThe APIC Audit Programme Version 5, July 2017
The APIC Audit Programme Version 5, July 2017 Table of contents 1 General 2. APIC Audit Programme 3 The Auditors 3.1 Educational Background and Experience 3.2 Auditor Training Courses for Certification
More informationHow to prepare an application for revision of a CEP
How to prepare an application for revision of a CEP P.Poukens-Renwart, PhD Certification of Substances Division EDQM Summary Validity of a CEP Revision background Types of revisions and examples How to
More informationDrug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel
Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel On February 13th, 2006, the FOOD AND DRUG ADMINISTRATION (FDA) implemented a revision to the Compliance Program Guidance Manual for active
More informationHow do you know the drug you are using is safe and effective?
The Chemistry, Manufacturing, and Controls (CMC) Technical Section: The Big Picture of a Long-term Commitment AAVPT Workshop February 28, 2011 James K. Nitao, Ph.D. Biotherapeutics Team Division of Manufacturing
More informationMedicine Variations Guideline
Medicine Variations Guideline National Health Regulatory Authority (NHRA) Kingdom of Bahrain 30 th March 2017 Version 2.0 Chief of Pharmaceutical Product Regulation: Dr/Roaya Al Abbasi Date: NHRA CEO Approval:
More informationCEP submission: How to prepare a New Application?
CEP submission: How to prepare a New Application? Nathalie Vicente Certification of Substances Division Summary How to prepare a New Application? Requirements for a new CEP application Content of the dossier
More informationJefferies 2015 Global Healthcare Conference June 3, 2015
Jefferies 2015 Global Healthcare Conference June 3, 2015 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationImplementation of ICH Q3D in the Certification Procedure
LS/CB PUBLIC DOCUMENT (LEVEL 1) PA/PH/CEP (16) 23 Strasbourg, August 2016 Certification of suitability to the Monographs of the European Pharmacopoeia Implementation of ICH Q3D in the Certification Procedure
More informationQuality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review
Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review Presented by Erika E. Englund, Ph.D. Slides courtesy of Dorota Matecka, Ph.D. Office of Pharmaceutical
More informationQuestion-based Review (QbR)
Question-based Review (QbR) Rebecca L. Owen, Ph.D. Team Leader, Feed/Topical Team Division of Manufacturing Technologies ONADE/CVM/FDA Outline Background on CMC Filing Requirements What is QbR? QbR at
More informationFuture of Question-based Review and Regulatory Submissions
Future of Question-based Review and Regulatory Submissions Robert Iser Associate Director for Policy Development (Acting) Office of Pharmaceutical Science / CDER / FDA FDA/PQRI Conference on Evolving Product
More informationRegulations of Biologics in Taiwan
Regulations of Biologics in Taiwan Churn-Shiouh Gau, Ph.D. Executive Director, Taiwan 2013/2/13 1 Outlines Regulation of Drugs in Taiwan - Organizations Regulations for Marketing Approval for Drugs including
More informationJefferies 2018 Global Healthcare Conference. June 7, 2018
Jefferies 2018 Global Healthcare Conference June 7, 2018 Forward-Looking Statements Statements in this presentation regarding the future financial and operating results, outlook, growth, prospects, business
More informationStephens Fall Investment Conference
Stephens Fall Investment Conference November 8, 2017 Steven M. Klosk President & CEO Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities
More informationASMF/DMF Quality Assessment Report (QAR) IGDRP Quality Working Group
ASMF/DMF Quality Assessment Report (QAR) IGDRP Quality Working Group Version Description of Change Author Effective Date v 1.0 Original publication ASMF/DMF WG May 26, 2015 v 1.1 Watermark added ASMF/DMF
More informationFDA Perspective on Standards and Recommendations for Control of Elemental Impurities in Drug Products
FDA Perspective on Standards and Recommendations for Control of Elemental Impurities in Drug Products AAPS Annual Meeting 27 October 2015 John F. Kauffman, Ph.D. CDER Office of Pharmaceutical Quality Division
More informationGAMP5 Validation for Dynamics 365
GAMP5 Validation for Dynamics 365 Prepared by: Michael Webster, Business Development Director, RSM US LLP michael.webster@rsmus.com, +1 617 241 1544 Dynamics 365 is an ideal enterprise resource planning
More informationFOREIGN DRUG INSPECTION/AUDITS FROM THE FDA PERSPECTIVE
FOREIGN DRUG INSPECTION/AUDITS FROM THE FDA PERSPECTIVE Robert C. Fish EAS Consulting Group, LLC. Statistics About 80% of world supply of APIs from India and China Some API produced in Korea, but little
More informationElemental Impurities Update from CVM
Elemental Impurities Update from CVM February 19, 2014 Michael Brent, Ph.D. Center for Veterinary Medicine Division of Manufacturing Technologies, HFV-146 USP and The elemental impurity limits
More informationQuestion-based Review: A New Quality Assessment System for Generic Drugs
Question-based Review: A New Quality Assessment System for Generic Drugs Lawrence X. Yu, Ph. D. Director for Science Office of Generic Drugs Food and Drug Administration IFPAC Annual Meeting, Jan. 25-28,
More informationPHARMACEUTICAL SCIENCES - QUESTIONS AND ANSWERS
PHARMACEUTICAL SCIENCES - QUESTIONS AND ANSWERS The document PHARMACEUTICAL SCIENCES - QUESTIONS AND ANSWERS is intended to provide clarification on a number of issues that relate to Quality (e.g., Chemistry
More informationInvestor Presentation RBC Capital Markets Global Healthcare Conference February 22, 2017
Investor Presentation 2017 RBC Capital Markets Global Healthcare Conference February 22, 2017 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private
More information